Savara Inc.

NASDAQ•SVRA

CEO: Mr. Matthew Pauls J.D., M.B.A.

セクター: Healthcare

業種: Biotechnology

上場日: 2017-04-28

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.

連絡先情報

1717 Langhorne Newtown Road, Suite 300, Langhorne, PA, 19047, United States

512-614-1848

www.savarapharma.com

時価総額

$1.13B

PER (TTM)

-10.4

17.4

配当利回り

52週高値

$7.01

52週安値

$1.89

52週レンジ

71%

順位58Top 85.6%

2.3

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 2.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.14+27.27%

直近4四半期の推移

フリーCF

-$22.53M-0.61%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

October Financing Bolsters Capital Raised approximately $140.0M net proceeds in October 2025 offering for working capital and MOLBREEVI development.

Liquidity Position Strengthened Cash and short-term investments totaled $124.4M as of September 30, 2025, supporting planned activities.

R&D Spending Rises Nine-month Research and Development expenses increased 10.5% to $60.5M, driven by manufacturing and regulatory costs.

New Debt Facility Secured Entered Hercules Loan Agreement providing up to $200M facility; initial $30M tranche repaid SVB Loan.

リスク要因

Regulatory Approval Uncertainty Received FDA Refusal to File letter in May 2025; future success hinges on BLA resubmission timing.

Ongoing Litigation Exposure Facing stockholder securities class action claims regarding regulatory and BLA filings; outcome uncertain.

Continued Operating Losses Incurred $86.6M net loss for nine months; expects continued losses funding development until commercialization.

FDA Operations Delayed Government shutdown beginning October 2025 impacts FDA funding, potentially delaying BLA acceptance or review timing.

見通し

BLA Resubmission Planned Company plans to resubmit the MOLBREEVI BLA in December 2025 and will request Priority Review status.

Royalty Financing Secured Entered agreement for $75.0M upon approval, subject to tiered royalty payments on future U.S. Net Sales.

Increased Manufacturing Investment Expect significant future R&D expenses, including investment in developing a second source manufacturer for supplies.

Capital Use Defined Net proceeds intended for MOLBREEVI clinical development, regulatory pursuit, and commercial launch preparation activities.

同業比較

売上高 (TTM)

GERN

$183.88M

+138.8%

RGNX

$170.44M

+104.5%

KURA

$67.48M

+25.2%

粗利益率 (最新四半期)

NBTX

100.0%

+0.0pp

ATXS

100.0%

+0.0pp

GOSS

100.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
TNGX	$1.97B	-19.4	-50.3%	8.4%
TYRA	$1.96B	-18.2	-41.2%	2.1%
NBTX	$1.61B	-26.6	76.7%	113.4%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月26日

EPS:-$0.12

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし